Understanding why some patients don't respond to bee venom allergy treatment
Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure
This study looks at why some people with bee venom allergies don't get better with treatment and tries to find out if certain allergens make the treatment less effective.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 266 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Medical University of Graz Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 3 sites (Graz and 2 other locations) |
| Trial ID | NCT04259359 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the effectiveness of venom immunotherapy (VIT) for patients with bee venom allergy, focusing on the role of predominant sensitizations to specific bee venom allergens as potential risk factors for treatment failure. The study aims to analyze patients who have experienced systemic anaphylactic reactions to bee stings and are undergoing VIT. By identifying the relationship between allergen sensitization and treatment outcomes, the research seeks to optimize bee venom preparations for better efficacy in future therapies.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 70 who have a history of severe allergic reactions to bee stings and are starting bee venom immunotherapy.
Not a fit: Patients who have contraindications to venom immunotherapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with bee venom allergies, enhancing the effectiveness of immunotherapy.
How similar studies have performed: While there is existing research on venom immunotherapy, this specific focus on predominant sensitizations as a risk factor for treatment failure is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Legally competent male and female subjects aged from 18 to 70 years with a history of a systemic anaphylactic sting reaction (≥ grade I according to the classification of Ring and Messmer) after bee stings, who will receive bee venom immunotherapy Exclusion Criteria: * Contraindications to VIT
Where this trial is running
Graz and 2 other locations
- Department of Dermatology and Venerology, Medical University of Graz — Graz, Austria (Recruiting)
- Elbe Klinikum Buxtehude — Buxtehude, Germany (Recruiting)
- Hospital Universitario de Castellón — Castellon, Spain (Recruiting)
Study contacts
- Study coordinator: Gunter J Sturm, MD, PhD
- Email: gunter.sturm@medunigraz.at
- Phone: +4331638580318
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.